Capivasertib: First Targeted Therapy Drug for Luminal A Breast Cancer Treatment in AKT Inhibitors
DOI:
https://doi.org/10.64960/srimedj.v41i5.270196Keywords:
capivasertib, targeted therapy drug, AKT inhibitors, breast cancerAbstract
Breast cancer is very important because it is the most common cancer that leading to cause of death among women worldwide. It can be divided into four subtypes by using molecular subtype including luminal A (ER positive/PR positive/HER2 negative), luminal B (ER positive/PR negative/HER2 negative), HER2 enriched and basal like or triple negative. Capivasertib is the targeted chemotherapy drug in AKT inhibitor group used in breast cancer treatment. This drug is also the first targeted therapy drug in AKT inhibitor group that has been approved by US Food and Drug Administration (US-FDA). It has efficacy in inhibiting tumor in advanced stage that have metastasis potential to nearby lymph node. This article is written to review basic knowledge and an application for further treatment in the future.
References
International Agency for Research on Cancer. Cancer today [Internet]. Lyon: International Agency for Research on Cancer; 2024 [cited Aug 5, 2026]. Available from: https://gco.iarc.who.int/today
National Cancer Institute. Cancer statistics [Internet]. Bangkok: National Cancer Institute; [date unknown] [cited Aug 5, 2026]. Available from: https://www.nci.go.th/Cancer_Statistics
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019;321(3):288-300. doi:10.1001/jama.2018.19323
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-52. doi:10.1038/35021093
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98(19):10869-74. doi:10.1073/pnas.191 367098
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel Members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22(8):1736-47. doi:10.1093/annonc/mdr304
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN clinical practice guidelines in oncology: breast cancer. Version 4.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025. Available from: https://studylib.net/doc/27955006/breast-v4?p=2
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(8): 1194-220. doi:10.1093/annonc/mdz189
MSD Manual Professional Edition. Breast cancer [Internet]. 2024 [cited Aug 5, 2026]. Available from: https://www.msdmanuals.com/professional/gyne-cology-and-obstetrics/breast-cancer/breast-cancer
NHS. Treatment for breast cancer in women [Internet]. 2024 [cited Aug 5, 2026]. Available from: https://www.nhs.uk/conditions/breast-cancer-in-women/treatment-for-breast-cancer-in-women/
Cusabio. AKT-PI3K pathway [Internet]. 2024 [cited 2025 Apr 4]. Available from: https://www.cusabio.com/pathway/PI3K-Akt-signaling-pathway.html
Hinz N, Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal 2019;17:154. doi:10.1186/s12964-019-0450-3
Xiao W, Zhang G, Chen B, Chen X, Wen L, Lai J, et al. Mutational landscape of PI3K-AKT-mTOR pathway in breast cancer: implications for targeted therapeutics. J Cancer 2021;12(14):4408-17. doi:10.7150/jca.52993
Riggio M, Perrone MC, Polo ML, Rodriguez MJ, May M, Abba M, et al. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep 2017;7:44244. doi:10.1038/srep44244
Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, et al. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice. Cell Signal 2014;26(5):1021-9. doi:10.1016/j.cell-sig.2014.01.018
Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1(9):707-17. doi:10.1158/1535-7163.MCT-01-0707
Dong C, Zhang J, Fang S, Liu F. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol 2021;12:628690. doi:10.3389/fphar.2021.628690
Kaboli PJ, Rahmat A, Ismail P, Ling KH. Chemore-sistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy. Am J Cancer Res 2021;11(10):5155-83. Available from: https://pubmed.ncbi.nlm.nih.gov/34765318/
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380(20):1929-40. doi:10.1056/NEJMoa1813904
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6): 520-9. doi:10.1056/NEJMoa1109653
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [Internet]. Plymouth Meeting (PA): NCCN; 2025 [cited Aug 5, 2026]. Available from: https://www.nccn.org
PubChem. Capivasertib. PubChem compound summary [Internet]. Bethesda (MD): National Center for Biotechnology Information; 2004 [cited Aug 5, 2026]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Capivasertib
Center for Drug Evaluation and Research. FDA approves capivasertib with fulvestrant for breast cancer [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2024 [cited 2026 August 5]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-ap-proves-capivasertib-fulvestrant-breast-cancer
Andrikopoulou A, Zografos E, Liontos M, Dimopoulos MA, Zagouri F. The emerging role of capivasertib in breast cancer. Breast 2022;63:157-67. doi:10.1016/j.breast.2022.03.018
Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004;90(Suppl 1). doi:10.1038/sj.bjc.6601629
Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer 2005;6(Suppl 1). doi:10.3816/CBC.2005.s.008
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 2023;388(22):2058-70. doi:10.1056/NEJ-Moa2214131
Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022;23(7):851-64. doi:10.1016/S1470-2045(22)00284-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
